Cytokine Antibody Array Assays Developed by RayBiotech Used to Identify Key Cancer Cell Chemoresistance Pathway
Published: Aug 21, 2012
NORCROSS, GA--(Marketwire - August 20, 2012) -
Nature. 2012 Jul 26; 487:500-4
Commenting on the research, RayBiotech's President and Chief Operating Officer Rani Huang stated, "The findings of this research have comprehensively outlined a novel mechanism behind the acquisition of chemoresistance by one of the deadliest forms of cancer. We are pleased that RayBiotech's antibody arrays played important roles in chemoresistance pathway characterization. This is a perfect example of how our high-content screening tools can facilitate potential drug target identification."
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001, RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for high quality and innovative developments in the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
For More Information:
Rob Burgess, PhD
Director, Business Development
Email: Email Contact